Literature DB >> 17956317

Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced dysfunction.

M J Rowan1, I Klyubin, Q Wang, N W Hu, R Anwyl.   

Abstract

There is growing evidence that mild cognitive impairment in early AD (Alzheimer's disease) may be due to synaptic dysfunction caused by the accumulation of non-fibrillar, oligomeric Abeta (amyloid beta-peptide), long before widespread synaptic loss and neurodegeneration occurs. Soluble Abeta oligomers can rapidly disrupt synaptic memory mechanisms at extremely low concentrations via stress-activated kinases and oxidative/nitrosative stress mediators. Here, we summarize experiments that investigated whether certain putative receptors for Abeta, the alphav integrin extracellular cell matrix-binding protein and the cytokine TNFalpha (tumour necrosis factor alpha) type-1 death receptor mediate Abeta oligomer-induced inhibition of LTP (long-term potentiation). Ligands that neutralize TNFalpha or genetic knockout of TNF-R1s (type-1 TNFalpha receptors) prevented Abeta-triggered inhibition of LTP in hippocampal slices. Similarly, antibodies to alphav-containing integrins abrogated LTP block by Abeta. Protection against the synaptic plasticity-disruptive effects of soluble Abeta was also achieved using systemically administered small molecules targeting these mechanisms in vivo. Taken together, this research lends support to therapeutic trials of drugs antagonizing synaptic plasticity-disrupting actions of Abeta oligomers in preclinical AD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17956317     DOI: 10.1042/BST0351219

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  49 in total

Review 1.  Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease.

Authors:  Qin Nie; Xiao-guang Du; Mei-yu Geng
Journal:  Acta Pharmacol Sin       Date:  2011-04-18       Impact factor: 6.150

Review 2.  Protective actions of sex steroid hormones in Alzheimer's disease.

Authors:  Christian J Pike; Jenna C Carroll; Emily R Rosario; Anna M Barron
Journal:  Front Neuroendocrinol       Date:  2009-05-07       Impact factor: 8.606

3.  Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism.

Authors:  Edward Tobinick
Journal:  Medscape J Med       Date:  2008-06-10

Review 4.  Alzheimer's disease amyloid beta-protein and synaptic function.

Authors:  Tomas Ondrejcak; Igor Klyubin; Neng-Wei Hu; Andrew E Barry; William K Cullen; Michael J Rowan
Journal:  Neuromolecular Med       Date:  2009-09-16       Impact factor: 3.843

Review 5.  Integrins in synapse regulation.

Authors:  Yun Kyung Park; Yukiko Goda
Journal:  Nat Rev Neurosci       Date:  2016-11-04       Impact factor: 34.870

6.  Inherent anti-amyloidogenic activity of human immunoglobulin gamma heavy chains.

Authors:  Sharad P Adekar; Igor Klyubin; Sally Macy; Michael J Rowan; Alan Solomon; Scott K Dessain; Brian O'Nuallain
Journal:  J Biol Chem       Date:  2009-11-04       Impact factor: 5.157

Review 7.  Neurodegenerative dementia and parkinsonism.

Authors:  A Gabelle; F Portet; C Berr; J Touchon
Journal:  J Nutr Health Aging       Date:  2010-01       Impact factor: 4.075

8.  Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease.

Authors:  Jennifer L Furman; Diana M Sama; John C Gant; Tina L Beckett; M Paul Murphy; Adam D Bachstetter; Linda J Van Eldik; Christopher M Norris
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

9.  Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging.

Authors:  Edward L Tobinick; Kai Chen; Xiaoyuan Chen
Journal:  BMC Res Notes       Date:  2009-02-27

10.  Acyl peptide hydrolase degrades monomeric and oligomeric amyloid-beta peptide.

Authors:  Rina Yamin; Cheng Zhao; Peter B O'Connor; Ann C McKee; Carmela R Abraham
Journal:  Mol Neurodegener       Date:  2009-07-23       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.